Nanomedicine-based Combination of Dexamethasone Palmitate and MCL-1 SiRNA for Synergistic Therapeutic Efficacy Against Rheumatoid Arthritis

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2021 Jul 31

PMID 34331261

Citations 7

Authors

Yanmei Li

Shitong Wei

Yonghua Sun

Shihua Zong

Yameng Sui

Affiliations

Soon will be listed here.

Abstract

The main aim of this research was to design a MCL-1 siRNA and dexamethasone (DEX)-loaded folate modified poly(lactide-co-glycolide) (PLGA)-based polymeric micelles with an eventual goal to improve the therapeutic outcome in the rheumatoid arthritis (RA). Polymeric micelles encapsulating the MCL-1 siRNA and DEX was successfully developed and observed to be stable. Physicochemical characteristics such as particle size and particle morphology were ideal for the systemic administration. Folate-conjugated DEX/siRNA-loaded polymeric micelles (DS-FPM) significantly lowered the MCL-1 mRNA expression compared to either DEX/siRNA-loaded polymeric micelles (DS-PM) or free siRNA in Raw264.7 cells and macrophage cells suggesting the importance of targeted nanocarriers. Most importantly, DS-FPM exhibited a greatest decrease in the hind paw volume with lowest clinical score compared to any other treated group indicating a superior anti-inflammatory activity. DS-FPM showed significantly lower levels of the TNF-α and IL-1β compared to AIA model and free groups. The folate receptor (FR)-targeting property of DS-FPM has been demonstrated to be a promising delivery platform for the effective delivery of combination therapeutics (siRNA and DEX) toward the treatment of rheumatoid arthritis.

Citing Articles

Optimized co-delivery of curcumin and methylprednisolone using polyvinyl alcohol-coated CuO nanoparticles for synergistic rheumatoid arthritis treatment.

Zarei K, Jahanbakhshi M, Nahavandi R, Emadi R Heliyon. 2024; 10(22):e40429.

PMID: 39641028 PMC: 11617928. DOI: 10.1016/j.heliyon.2024.e40429.

Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms.

Zamanian M, Zafari H, Osminina M, Skakodub A, Aboqader Al-Aouadi R, Golmohammadi M Animal Model Exp Med. 2024; 8(1):5-19.

PMID: 39627850 PMC: 11798740. DOI: 10.1002/ame2.12518.

Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges.

Ren S, Xu Y, Dong X, Mu Q, Chen X, Yu Y J Nanobiotechnology. 2024; 22(1):431.

PMID: 39034407 PMC: 11265020. DOI: 10.1186/s12951-024-02670-7.

Prodrug-based nanomedicines for rheumatoid arthritis.

Li P, Wang C, Huo H, Xu C, Sun H, Wang X Discov Nano. 2024; 19(1):9.

PMID: 38180534 PMC: 10769998. DOI: 10.1186/s11671-023-03950-1.

Lipid nanocarrier targeting activated macrophages for antiretroviral therapy of HIV reservoir.

Wu D, Si M, Xue H, Tran N, Khalili K, Kaminski R Nanomedicine (Lond). 2023; 18(20):1343-1360.

PMID: 37815117 PMC: 10652294. DOI: 10.2217/nnm-2023-0120.

References

Firestein G . Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937):356-61. DOI: 10.1038/nature01661. View

Bax M, Heemst J, Huizinga T, Toes R . Genetics of rheumatoid arthritis: what have we learned?. Immunogenetics. 2011; 63(8):459-66. PMC: 3132380. DOI: 10.1007/s00251-011-0528-6. View

Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E . Diagnosis and classification of rheumatoid arthritis. J Autoimmun. 2014; 48-49:26-30. DOI: 10.1016/j.jaut.2014.01.027. View

Smolen J, Aletaha D, McInnes I . Rheumatoid arthritis. Lancet. 2016; 388(10055):2023-2038. DOI: 10.1016/S0140-6736(16)30173-8. View

Abbasi M, Mousavi M, Jamalzehi S, Alimohammadi R, Bezvan M, Mohammadi H . Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2018; 234(7):10018-10031. DOI: 10.1002/jcp.27860. View

Singh J, Saag K, Bridges Jr S, Akl E, Bannuru R, Sullivan M . 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 68(1):1-26. DOI: 10.1002/art.39480. View

Mateen S, Zafar A, Moin S, Khan A, Zubair S . Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta. 2016; 455:161-71. DOI: 10.1016/j.cca.2016.02.010. View

Chu J, Wang X, Bi H, Li L, Ren M, Wang J . Dihydromyricetin relieves rheumatoid arthritis symptoms and suppresses expression of pro-inflammatory cytokines via the activation of Nrf2 pathway in rheumatoid arthritis model. Int Immunopharmacol. 2018; 59:174-180. DOI: 10.1016/j.intimp.2018.04.001. View

Liu H, Eksarko P, Temkin V, Haines 3rd G, Perlman H, Koch A . Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2005; 175(12):8337-45. DOI: 10.4049/jimmunol.175.12.8337. View

10.

Liu H, Huang Q, Shi B, Eksarko P, Temkin V, Pope R . Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2006; 54(10):3174-81. DOI: 10.1002/art.22132. View

11.

Schiffelers R, Xu J, Storm G, Woodle M, Scaria P . Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum. 2005; 52(4):1314-8. DOI: 10.1002/art.20975. View

12.

Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell D . Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019; 380(6):549-558. DOI: 10.1056/NEJMoa1807838. View

13.

Agarwal S, Simon A, Goel V, Habtemariam B, Clausen V, Kim J . Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria. Clin Pharmacol Ther. 2020; 108(1):63-72. DOI: 10.1002/cpt.1802. View

14.

Pecot C, Calin G, Coleman R, Lopez-Berestein G, Sood A . RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2010; 11(1):59-67. PMC: 3199132. DOI: 10.1038/nrc2966. View

15.

Wei X, Wu J, Zhao G, Galdamez J, Lele S, Wang X . Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis. Mol Pharm. 2018; 15(8):3456-3467. PMC: 6078779. DOI: 10.1021/acs.molpharmaceut.8b00433. View

16.

Wei X, Li F, Zhao G, Chhonker Y, Averill C, Galdamez J . Pharmacokinetic and Biodistribution Studies of HPMA Copolymer Conjugates in an Aseptic Implant Loosening Mouse Model. Mol Pharm. 2017; 14(5):1418-1428. PMC: 5906048. DOI: 10.1021/acs.molpharmaceut.7b00045. View

17.

Zhang Y, Jia Z, Yuan H, Dusad A, Ren K, Wei X . The Evaluation of Therapeutic Efficacy and Safety Profile of Simvastatin Prodrug Micelles in a Closed Fracture Mouse Model. Pharm Res. 2016; 33(8):1959-71. PMC: 4945391. DOI: 10.1007/s11095-016-1932-2. View

18.

Ramasamy T, Ruttala H, Gupta B, Poudel B, Choi H, Yong C . Smart chemistry-based nanosized drug delivery systems for systemic applications: A comprehensive review. J Control Release. 2017; 258:226-253. DOI: 10.1016/j.jconrel.2017.04.043. View

19.

Tong Z, Cheng L, Song J, Wang M, Yuan J, Li X . Therapeutic effects of Caesalpinia minax Hance on complete Freund's adjuvant (CFA)-induced arthritis and the anti-inflammatory activity of cassane diterpenes as main active components. J Ethnopharmacol. 2018; 226:90-96. DOI: 10.1016/j.jep.2018.08.011. View

20.

Zheng N, Lian B, Xu G, Liu X, Li X, Ji J . Development of a Subcellular Semimechanism-Based Pharmacokinetic/Pharmacodynamic Model to Characterize Paclitaxel Effects Delivered by Polymeric Micelles. J Pharm Sci. 2018; 108(1):725-731. DOI: 10.1016/j.xphs.2018.10.062. View